AXA Framlington Biotech R
|Bid Price||-||Offer Price||-|
|Mid Price||USX 98.07||Day Change||USX -0.61 (-0.76%)|
|Price Date||20 Jan 2017||Crown Rating|
|Shares Class||Inc.||Yield||0.00 %|
|Total Expense Ratio||0.00||Fund Size||532,751,300.00|
|Launch Date||26/11/2001||Standard Initial Charge (%)||0.00|
|Annual Management Charge (%)||0.00||Sector||IMA UK Equity Income|
|Min Investment (£)||0.00||Total Expense Ratio (%)||0.00|
|ISIN||Min TopUp (£)||0.00|
To provide long-term capital appreciation by investing principally in equity securities of companies in the biotechnology, genomic and medical research industries worldwide.
Linden Thomson joined AXA IM in June 2011 as sector specialist on the Healthcare equity desk. Linden joined AXA IM from Hedge Fund Clear River Capital where she was responsible for fundamental stock research across the global pharmaceutical and biotechnology sectors. Prior to that she worked for Goldman Sachs on the sell side where she was based in the healthcare research team with specific focus on the biotechnology sector. She graduated from Edinburgh University with a BSc in Medical Microbiology and is a CFA Charterholder.